Physician profile
Terry Baksh
NPI 1710962428
$10,869.83
in general payments reported to CMS, 2019-2025
49 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $1,022 · 2021: $1,702 · 2022: $1,720 · 2023: $1,534 · 2024: $1,790 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.20 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,884.49 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,341.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $919.38 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $811.58 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $666.21 | 2020-2025 | Jardiance, Tradjenta, Ofev |
| Astellas Pharma US INC | $579.08 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $534.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $507.61 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $351.05 | 2019-2023 | |
| Amarin Pharma, INC. | $290.76 | 2019-2023 | |
| Allergan, INC. | $286.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $276.45 | 2019-2021 | |
| Exact Sciences Corporation | $199.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $195.32 | 2023-2024 | Korlym |
| Sumitomo Pharma America, INC. | $174.10 | 2023-2025 | Gemtesa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Baksh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.